The Atrial Fibrillation Surgery Market is expected to register a CAGR of nearly 12.2% during the forecast period.
COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.
Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimize the risk of exposure to COVID-19. New technologies and digital platforms to aid in remote care should be developed, and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the studied market.
The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.
Additionally, the launch of new products in the market will further boost the market growth. For instance, in April 2022, AtriCure, Inc. launched the EnCompass Clamp, a part of the Isolator Synergy Ablation System in the United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.
Furthermore, the rising research and development procedures highlighting the advancements in the Atrial fibrillation market will also boost the market. For instance, in January 2022, Peerbridge Health collaborated with Northwell Health on their newly launched AFib Center of Excellence, a multi-disciplinary effort that optimizes treatment for patients with atrial fibrillation (AFib). With Peerbridge's support, Northwell's AFib Center of Excellence will conduct a pilot program focusing on AFib patients with undiagnosed obstructive sleep apnea (OSA). The pilot aims to help cardiology and sleep physicians better understand the critical link between the two conditions and how best to quickly and effectively treat AFib and OSA concurrently. Thus, advancements in atrial fibrillation therapeutics are expected to drive the market.
Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period. However, the high cost of procedures and regulatory issues associated with these devices is expected to hinder the market growth.
The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.
The addition of multiple services in advancing ambulatory surgical centers will further drive the market growth. For instance, in January 2021, HST Pathways launched a premier membership program for ambulatory surgery centers (ASCs), “HST One.” This membership program will enable its end-user to select bundled popular products as part of their membership, with the flexibility to add additional services as needed. Such initiation of delivering customized services at ambulatory surgical centers will attract a greater number of patients and will lead to significant growth of the market.
In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.
Furthermore, the article "Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in Traditional Nonambulatory and Freestanding Ambulatory Settings" published in April 2022, the periprocedural management of patients who receive catheter ablation for AF is similar to those undergoing ambulatory surgery. Thus, such advancements in ambulatory surgical centers for the smooth transition of atrial fibrillation surgeries will drive the segment growth.
Thus, due to the above-mentioned factors, the studied segment is expected to contribute significantly to market growth.
The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. The United States within the North American region is expected to dominate the market growth. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in September 2021, it is estimated that 12.1 million people in the United States will have atrial fibrillation in 2030, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future.
With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in the United States. For instance, in July 2020, Boston Scientific Corporation received the United States Food and Drug Administration approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.
Additionally, in February 2022, Medtronic plc received United States Food and Drug Administration approval for Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
Furthermore, growing research and development for proving the efficacies of existing products in the region will increase their adoption, thereby driving the market. For instance, in April 2022, CathVision reported the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center. ECGenius represents an important evolution in the quality of ECG signal acquisition, interpretation, and therapy support which help in correctly diagnosing and devising ablation strategies for complex arrhythmias, including atrial fibrillation (AF).
Thus, due to the above-mentioned factors, the studied market is expected to grow in the region during the study period.
The studied market is fragmented and moderately competitive. The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing the penetration of new entrants in the market. Technological advancements and the focus on improving the healthcare system are expected to influence more companies to enter the market, further driving market growth in the future. Major key players in the market include Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure Inc., and Cardiofocus Inc., among others.
This product will be delivered within 2 business days.
COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.
Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimize the risk of exposure to COVID-19. New technologies and digital platforms to aid in remote care should be developed, and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the studied market.
The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.
Additionally, the launch of new products in the market will further boost the market growth. For instance, in April 2022, AtriCure, Inc. launched the EnCompass Clamp, a part of the Isolator Synergy Ablation System in the United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.
Furthermore, the rising research and development procedures highlighting the advancements in the Atrial fibrillation market will also boost the market. For instance, in January 2022, Peerbridge Health collaborated with Northwell Health on their newly launched AFib Center of Excellence, a multi-disciplinary effort that optimizes treatment for patients with atrial fibrillation (AFib). With Peerbridge's support, Northwell's AFib Center of Excellence will conduct a pilot program focusing on AFib patients with undiagnosed obstructive sleep apnea (OSA). The pilot aims to help cardiology and sleep physicians better understand the critical link between the two conditions and how best to quickly and effectively treat AFib and OSA concurrently. Thus, advancements in atrial fibrillation therapeutics are expected to drive the market.
Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period. However, the high cost of procedures and regulatory issues associated with these devices is expected to hinder the market growth.
Key Market Trends
The Ambulatory Surgical Center Segment is Expected to Witness Good Growth over the Forecast Period
The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.
The addition of multiple services in advancing ambulatory surgical centers will further drive the market growth. For instance, in January 2021, HST Pathways launched a premier membership program for ambulatory surgery centers (ASCs), “HST One.” This membership program will enable its end-user to select bundled popular products as part of their membership, with the flexibility to add additional services as needed. Such initiation of delivering customized services at ambulatory surgical centers will attract a greater number of patients and will lead to significant growth of the market.
In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.
Furthermore, the article "Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in Traditional Nonambulatory and Freestanding Ambulatory Settings" published in April 2022, the periprocedural management of patients who receive catheter ablation for AF is similar to those undergoing ambulatory surgery. Thus, such advancements in ambulatory surgical centers for the smooth transition of atrial fibrillation surgeries will drive the segment growth.
Thus, due to the above-mentioned factors, the studied segment is expected to contribute significantly to market growth.
North America is the Major Growing Segment Over the Forecast Period
The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. The United States within the North American region is expected to dominate the market growth. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in September 2021, it is estimated that 12.1 million people in the United States will have atrial fibrillation in 2030, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future.
With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in the United States. For instance, in July 2020, Boston Scientific Corporation received the United States Food and Drug Administration approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.
Additionally, in February 2022, Medtronic plc received United States Food and Drug Administration approval for Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
Furthermore, growing research and development for proving the efficacies of existing products in the region will increase their adoption, thereby driving the market. For instance, in April 2022, CathVision reported the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center. ECGenius represents an important evolution in the quality of ECG signal acquisition, interpretation, and therapy support which help in correctly diagnosing and devising ablation strategies for complex arrhythmias, including atrial fibrillation (AF).
Thus, due to the above-mentioned factors, the studied market is expected to grow in the region during the study period.
Competitive Landscape
The studied market is fragmented and moderately competitive. The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing the penetration of new entrants in the market. Technological advancements and the focus on improving the healthcare system are expected to influence more companies to enter the market, further driving market growth in the future. Major key players in the market include Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure Inc., and Cardiofocus Inc., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - in USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boston Scientific Corporation
- Medtronic PLC
- Biotronik SE & Co. KG
- AtriCure Inc.
- Cardiofocus Inc.
- Abbott Laboratories
- Johnson & Johnson
- MicroPort Scientific Corporation
- Koninklijke Philips NV
- Siemens AG
- Osypka AG
- Kardium Inc.
Methodology
LOADING...
